Murray Dallan 4
4 · Sarepta Therapeutics, Inc. · Filed Jun 25, 2024
Insider Transaction Report
Form 4
Murray Dallan
Chief Customer Officer
Transactions
- Exercise/Conversion
Performance Stock Units
2024-06-21−6,250→ 0 total→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2024-06-21+6,250→ 24,375 total - Tax Payment
Common Stock
2024-06-24$164.64/sh−2,352$387,233→ 22,023 total - Award
Performance Stock Units
2024-06-21+5,500→ 5,500 total→ Common Stock (5,500 underlying) - Award
Performance Stock Units
2024-06-21+6,250→ 6,250 total→ Common Stock (6,250 underlying)
Footnotes (3)
- [F1]Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.
- [F2]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024.
- [F3]Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.